EXACT Sciences (EXAS) Rating Reiterated by William Blair
EXACT Sciences (NASDAQ:EXAS)‘s stock had its “buy” rating reaffirmed by equities research analysts at William Blair in a research note issued on Wednesday.
Other analysts have also recently issued reports about the company. Jefferies Group upped their price objective on EXACT Sciences to $60.00 and gave the stock a “buy” rating in a report on Tuesday, October 31st. Bank of America set a $56.00 price objective on EXACT Sciences and gave the stock a “buy” rating in a report on Thursday, October 19th. Robert W. Baird reaffirmed a “buy” rating and set a $49.00 price objective on shares of EXACT Sciences in a report on Friday, October 6th. Canaccord Genuity reaffirmed a “buy” rating and set a $60.00 price objective (up from $45.00) on shares of EXACT Sciences in a report on Tuesday, October 3rd. Finally, Zacks Investment Research raised EXACT Sciences from a “hold” rating to a “buy” rating and set a $51.00 price objective on the stock in a report on Tuesday, September 26th. Eight analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. EXACT Sciences has a consensus rating of “Buy” and a consensus target price of $50.58.
EXACT Sciences (EXAS) traded down $0.77 during midday trading on Wednesday, reaching $51.70. The company had a trading volume of 892,490 shares, compared to its average volume of 3,257,083. The stock has a market cap of $6,220.00, a PE ratio of -44.96 and a beta of 0.68. EXACT Sciences has a one year low of $16.95 and a one year high of $63.60. The company has a current ratio of 10.34, a quick ratio of 9.98 and a debt-to-equity ratio of 0.01.
In other news, insider Kevin T. Conroy sold 134,057 shares of the business’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $59.50, for a total transaction of $7,976,391.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP D Scott Coward sold 1,665 shares of the business’s stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $52.54, for a total value of $87,479.10. Following the transaction, the senior vice president now directly owns 37,558 shares in the company, valued at approximately $1,973,297.32. The disclosure for this sale can be found here. In the last three months, insiders have sold 610,433 shares of company stock worth $34,341,306. Corporate insiders own 4.00% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio increased its position in shares of EXACT Sciences by 69.7% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 122,201 shares of the medical research company’s stock valued at $5,758,000 after purchasing an additional 50,185 shares during the last quarter. Piedmont Investment Advisors LLC bought a new position in EXACT Sciences in the 3rd quarter valued at $514,000. California Public Employees Retirement System grew its position in EXACT Sciences by 2.8% in the 3rd quarter. California Public Employees Retirement System now owns 190,338 shares of the medical research company’s stock valued at $8,969,000 after acquiring an additional 5,238 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. grew its position in EXACT Sciences by 117.9% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,730 shares of the medical research company’s stock valued at $327,000 after acquiring an additional 3,642 shares during the last quarter. Finally, AlphaStar Capital Management LLC bought a new position in EXACT Sciences in the 3rd quarter valued at $322,000. 82.39% of the stock is currently owned by hedge funds and other institutional investors.
EXACT Sciences Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.